文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy.

作者信息

Tanaka Koji, Mori Ryusaburo, Wakatsuki Yu, Onoe Hajime, Kawamura Akiyuki, Nakashizuka Hiroyuki

机构信息

Department of Ophthalmology, Nihon University School of Medicine, Tokyo 101-8309, Japan.

出版信息

J Clin Med. 2021 May 17;10(10):2168. doi: 10.3390/jcm10102168.


DOI:10.3390/jcm10102168
PMID:34067863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8155862/
Abstract

Pachychoroid neovasculopathy (PNV) is treated with antivascular endothelial growth factor (VEGF) injection and photodynamic therapy (PDT), but no curative treatment has yet been established. We aimed to clarify the treatment results of a reduced dose of PDT for PNV. The subjects were 27 eyes of 27 patients (male:female = 20:7, mean age 58.9 years). PDT, at 2/3 of the conventional dose (2/3PDT), was administered once. The patients were then observed for one year. Eyes with polypoidal choroidal vasculopathy (PCV) were excluded. We investigated the associations among the central retinal thickness, choroidal thickness, and visual acuity changes before treatment and one, three, six and 12 months after PDT. When serous retinal detachment was increased or unchanged or new hemorrhages were observed, as compared with pretreatment findings, intravitreal injection of an anti-VEGF agent was performed. Visual acuity was significantly improved, as compared to before treatment, at three, six, and 12 months after 2/3PDT. Foveal retinal thickness was significantly decreased after versus before treatment in the 2/3PDT group ( < 0.001). Foveal choroidal thickness was also significantly reduced in the 2/3PDT group ( = 0.001). Additional intravitreal anti-VEGF agent injections were administered to three patients (11%), while 24 (89%) required no additional treatment during the one-year follow-up period. For PNV without polyps, 2/3PDT appears to be effective.

摘要

相似文献

[1]
Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy.

J Clin Med. 2021-5-17

[2]
One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.

Jpn J Ophthalmol. 2020-3

[3]
Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.

Jpn J Ophthalmol. 2020-5

[4]
Occlusion of a Vortex Vein After Treatment With Half-Fluence Photodynamic Therapy Combined With Intravitreal Aflibercept Injection for Pachychoroid Neovasculopathy.

Cureus. 2022-8-4

[5]
Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.

Jpn J Ophthalmol. 2018-3

[6]
Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor.

Indian J Ophthalmol. 2019-10

[7]
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.

Indian J Ophthalmol. 2018-8

[8]
Wide-Field Choroidal Thickness Analysis after Half-Fluence Photodynamic Therapy Combined with Intravitreal Aflibercept Injection in Pachychoroid Neovasculopathy.

J Clin Med. 2024-3-11

[9]
Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.

Invest Ophthalmol Vis Sci. 2018-2-1

[10]
Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.

Ophthalmologica. 2011-1-27

引用本文的文献

[1]
Anatomical and Functional Outcomes of Anti-VEGF Therapy in Pachychoroid Neovasculopathy.

Clin Ophthalmol. 2025-8-12

[2]
Japanese clinical guidelines for neovascular age-related macular degeneration.

Jpn J Ophthalmol. 2025-7-14

[3]
Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy.

Sci Rep. 2025-7-2

[4]
Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy.

Sci Rep. 2025-5-30

[5]
Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy.

Eye (Lond). 2023-11

[6]
Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy.

Graefes Arch Clin Exp Ophthalmol. 2023-8

[7]
Relationship between Pachychoroid and Polypoidal Choroidal Vasculopathy.

J Clin Med. 2022-8-8

本文引用的文献

[1]
One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy.

Graefes Arch Clin Exp Ophthalmol. 2020-6

[2]
One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.

Jpn J Ophthalmol. 2020-3

[3]
Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy.

J Ocul Pharmacol Ther. 2019-2-26

[4]
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy.

Sci Rep. 2019-2-14

[5]
Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Ophthalmologica. 2019

[6]
Pachychoroid disease.

Eye (Lond). 2018-7-11

[7]
Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization.

Am J Ophthalmol. 2018-6-27

[8]
Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy.

Br J Ophthalmol. 2019-4-17

[9]
Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.

Jpn J Ophthalmol. 2018-3

[10]
CHOROIDAL VASCULAR HYPERPERMEABILITY AS A PREDICTOR OF TREATMENT RESPONSE FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.

Retina. 2018-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索